Cachexia

Cachexia - Pipeline Insight, 2019 with Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 8, 2019
Health, Pharmaceutical, Medicine, Medical specialties, Health, Cachexia, Geriatrics, Rehabilitation medicine, Pipeline, Drug pipeline

The "Cachexia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cachexia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cachexia development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report covers pipeline activity across the complete product development cycle i.e.

Cancer Cachexia - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 13, 2019
Health, Oncology, Pharmaceutical, Medicine, Medical specialties, Health, Geriatrics, Rehabilitation medicine, Cachexia, Aging-associated diseases, Drug pipeline, Cancer

The "Cancer Cachexia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Cachexia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cancer Cachexia - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Cancer Cachexia development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for the Cancer Cachexia
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Cancer Cachexia

Pancreatic Cancer Action Network Addresses Pancreatic Cancer Weight Loss Causes And Treatment In Newly Published Paper

Retrieved on: 
Wednesday, January 2, 2019
Medicine, RTT, Health, Rehabilitation medicine, Cachexia, Geriatrics, Pancreatic Cancer Action Network, Pancreatic cancer, Cancer, Pancreatic Cancer Action

"It is important to distinguish the three causes of weight loss in pancreatic cancer patients," said Lynn Matrisian, PhD, MBA , chief science officer at PanCAN and a coauthor of the article.

Key Points: 
  • "It is important to distinguish the three causes of weight loss in pancreatic cancer patients," said Lynn Matrisian, PhD, MBA , chief science officer at PanCAN and a coauthor of the article.
  • An estimated 85 percent of pancreatic cancer patients suffer from cancer cachexia, a condition that causes patients to lose significant muscle mass.
  • Weight loss in pancreatic cancer patients can significantly lower patients' quality of life, ability to handle treatment and can impact survival.
  • The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world's toughest cancer.

Creative Medical Technology Holdings Aims to Treat Cancer Associated Wasting (Cachexia) Using AmnioStem Universal Donor Stem Cell

Retrieved on: 
Friday, July 6, 2018
Medicine, Biology, Clinical medicine, Cachexia, Geriatrics, Rehabilitation medicine, Immunology, Biotechnology, Tumor necrosis factor alpha, Inflammation, Stem cell

PHOENIX, July 6, 2018 /PRNewswire/ --Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today initiation of a program aimed at treating cancer associated wasting, through the in-licensing of patent application #15/814284entitled "Treatment of Cachexia Using Stem Cells and Products Thereof".

Key Points: 
  • PHOENIX, July 6, 2018 /PRNewswire/ --Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today initiation of a program aimed at treating cancer associated wasting, through the in-licensing of patent application #15/814284entitled "Treatment of Cachexia Using Stem Cells and Products Thereof".
  • Recently the Company announced data that the AmnioStem stem cell was superior to other stem cell types at reducing inflammatory mediators, including TNF-alpha1.
  • It is well known that inflammatory mediators generated by cancer have a pivotal contribution to cancer associated weight loss, formally termed "cachexia".
  • Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company trading on the OTCQB under the ticker symbol CELZ.